Rezipas

   
Google
 
Web NewDrugInformation.com

Rezipas


Drug - Rezipas
The trade name of the product as shown on the labeling.

Dosage - POWDER; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Aminosalicylic Acid Resin Complex
Multiple ingredients are in alphabetical order.

Strength - EQ 500MG BASE/GM
The potency of the active ingredient(s), Aminosalicylic Acid Resin Complex. May repeat for multiple part products.

Applicant - BRISTOL MYERS SQUIBB
The firm name holding legal responsibility for Rezipas. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 009052
The FDA assigned number to Rezipas. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Rezipas. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Approved Prior to Jan 1, 1982
The date Rezipas was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Rezipas. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Rezipas is in. Format is RX, OTC, DISCN.

Applicant Full Name - Bristol Myers Squibb Co
The full name of the firm holding legal responsibility for the new application of Rezipas.

Rezipas